Publications
Publications
Show Results For
- All HBS Web
(1,191)
- Faculty Publications (274)
Page 1 of 274
Results →
- March 2025
- Case
Niramai: An AI Solution to Save Lives
By: Rembrand Koning, Maria P. Roche and Kairavi Dey
Founded in 2017, Niramai developed Thermalytix, a breast cancer screening tool. Thermalytix used a high-resolution thermal sensing device and machine learning algorithms to analyze thermal images and detect tumors. Its patented solution leveraged big data analytics,... View Details
- February 2025
- Case
Abiomed: Clinical Trials and Tribulations
By: Satish Tadikonda, Faith Robertson and William Marks
After receiving 510(k) clearance for the Impella 2.5 device, Abiomed had proceeded to conduct a premarket approval (PMA) process as well to prove clinical superiority, earn greater protection, and extend commercial runway. However, in the middle of the clinical trial... View Details
- January 2025
- Case
A Tiger in the Tank: Exxon Sues Investors
By: Clayton S. Rose, Sarah Sasso and James Weber
In June 2024, investors were trying to make sense of ExxonMobil’s (Exxon) lawsuit against two impact investors, Arjuna Capital (Arjuna) and Follow This, that had just been dismissed by the U.S. District Court of Northern Texas. Exxon’s suit challenged the rights of two... View Details
Keywords: Disruption; Talent and Talent Management; Customer Satisfaction; Decision Making; Demographics; Ethics; Corporate Accountability; Employees; Recruitment; Retention; Leadership; Crisis Management; Risk Management; Corporate Social Responsibility and Impact; Mission and Purpose; Organizational Change and Adaptation; Civil Society or Community; Social Issues; Adaptation; Investment Activism; Lawsuits and Litigation; Business and Shareholder Relations; Medical Devices and Supplies Industry; Medical Devices and Supplies Industry; Medical Devices and Supplies Industry; United States; Netherlands; Norway
- January 2025
- Case
Shifting Winds: DEI in Corporate America
By: Clayton S. Rose, Maisie Wiltshire-Gordon and David Lane
In the 2020s, intense and conflicting social and political pressures challenged organizational leaders around the world. Prominent among these were powerful competing views on workplace diversity, equity, and inclusion programs (DEI) in the United States. Public... View Details
Keywords: Disruption; Leadership; Crisis Management; Risk Management; Corporate Social Responsibility and Impact; Mission and Purpose; Organizational Change and Adaptation; Organizational Culture; Civil Society or Community; Social Issues; Talent and Talent Management; Customer Satisfaction; Diversity; Ethics; Corporate Accountability; Employees; Retention; Recruitment; Adaptation; Programs; Agriculture and Agribusiness Industry; Agriculture and Agribusiness Industry; Agriculture and Agribusiness Industry; Agriculture and Agribusiness Industry; Agriculture and Agribusiness Industry; Agriculture and Agribusiness Industry; Agriculture and Agribusiness Industry; United States; Massachusetts; Maryland; Tennessee; District of Columbia
- November 2024
- Supplement
Epic Games: Nineteen Eighty-Fortnite (B)
By: Andy Wu and Ronald Wang
In a significant ruling on April 24, 2023, the U.S. Court of Appeals for the Ninth Circuit upheld portions of the district court’s decision against Epic Games back in September 2021. However, Apple’s anti-steering provisions, which restricted app developers from... View Details
- September–October 2024
- Article
Should a Family Business Accept a Returning Daughter’s Radical Proposal?
By: John D. Macomber
A family-owned and controlled conglomerate in Cote d'Ivoire, West Africa, has to decide what titles and authority to give to a daughter who is being courted to leave a promising career in Europe to come back and join the business. The choices of role range from an... View Details
- September 2024
- Case
Myeloma Investment Fund
By: Kyle Myers and Scott Sawaya
This case explores a critical decision facing the Myeloma Investment Fund (MIF) as it evaluates two investment opportunities aimed at accelerating a cure for multiple myeloma.
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
- July 2024
- Article
Buying the Verdict
By: Lauren Cohen and Umit Gurun
We document evidence that firms systematically increase specialized, locally targeted advertising following the firm being taken to trial in that given location, precisely following initiation of the suit. In particular, we use legal actions brought against publicly... View Details
- June 2024
- Article
Information Spillovers in Experience Goods Competition
By: Zhuoqiong Charlie Chen, Christopher Stanton and Catherine Thomas
When experience goods compete, consuming one product can be informative about value for similar untried products. We study a two-period model of duopoly competition in markets that have this feature and where firms can price discriminate between consumers based on... View Details
- April 2024
- Article
A Machine Learning Algorithm Predicting Risk of Dilating VUR among Infants with Hydronephrosis Using UTD Classification
By: Hsin-Hsiao Scott Wang, Michael Lingzhi Li, Dylan Cahill, John Panagides, Tanya Logvinenko, Jeanne Chow and Caleb Nelson
Backgrounds: Urinary Tract Dilation (UTD) classification has been designed to be a more objective grading system to evaluate antenatal and post-natal UTD. Due to unclear association between UTD classifications to specific anomalies such as vesico-ureteral reflux (VUR),... View Details
- 2024
- Working Paper
The Cram Method for Efficient Simultaneous Learning and Evaluation
By: Zeyang Jia, Kosuke Imai and Michael Lingzhi Li
We introduce the "cram" method, a general and efficient approach to simultaneous learning and evaluation using a generic machine learning (ML) algorithm. In a single pass of batched data, the proposed method repeatedly trains an ML algorithm and tests its empirical... View Details
Keywords: AI and Machine Learning
- February 2024
- Case
Compass Pathways: Pioneering Psychedelic Treatment
By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu
This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no... View Details
- February 2024
- Article
Representation and Extrapolation: Evidence from Clinical Trials
By: Marcella Alsan, Maya Durvasula, Harsh Gupta, Joshua Schwartzstein and Heidi L. Williams
This article examines the consequences and causes of low enrollment of Black patients in clinical
trials. We develop a simple model of similarity-based extrapolation that predicts that evidence is
more relevant for decision-making by physicians and patients when it... View Details
- January–February 2024
- Article
Shared Service Delivery Can Increase Client Engagement: A Study of Shared Medical Appointments
By: Ryan W. Buell, Kamalini Ramdas, Nazlı Sönmez, Kavitha Srinivasan and Rengaraj Venkatesh
Problem Definition: Clients and service providers alike often consider one-on-one service delivery to be ideal, assuming – perhaps unquestioningly – that devoting individualized attention best improves client outcomes. In contrast, in shared service delivery, clients... View Details
- December 2023 (Revised March 2024)
- Case
Manufacturing Moderna's Future
By: Satish Tadikonda and William Marks
In 2019, Moderna faced long odds of survival having failed to develop a successful clinical program out of the vast platform technology they had built around mRNA. Nearly overnight, the company skyrocketed to success with a vaccine for COVID-19, leading to an extremely... View Details
- November 2023 (Revised April 2024)
- Case
BiomX: Bringing Phage Back to the Stage
By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details
- September 2023
- Case
THREAD Research: Decentralized Clinical Trials and Beyond
By: Satish Tadikonda, Amanda McEwen and William Marks
- August 2023 (Revised May 2024)
- Case
Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations
By: Satish Tadikonda and Amanda McEwen
The success or failure of Dicerna Pharmaceuticals (Dicerna) as an emerging pharmaceutical company would likely hinge on its lead drug candidate Nedosiran and the company’s ability to see it successfully through clinical development. Ralf Rosskamp, Chief Medical... View Details
- July 2023 (Revised April 2024)
- Case
Raymond Jefferson: Trial by Fire
By: Anthony Mayo and Carin-Isabel Knoop
In the spring of 2021, Raymond (Ray) Jefferson applied for a job in President Joseph Biden’s administration. Ten years earlier, false allegations were used to force him to resign from his prior U.S. government position as Assistant Secretary of Labor for Veterans’... View Details
- July 2023
- Case
DayTwo: Going to Market with Gut Microbiome (Abridged)
By: Ayelet Israeli
DayTwo is a young Israeli startup that applies research on the gut microbiome and machine learning algorithms to deliver personalized nutritional recommendations to its users in order to minimize blood sugar spikes after meals. After a first year of trial rollout in... View Details